MedTrace Logo

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 740

Last updated 2026-03-13

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours.

The main question the study aims to answer are:

1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS.
2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS.

During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

JX10

JX10 is a thrombolytic agent.

DRUG

Placebo

Placebo is being used as the comparator.

Sponsors & Collaborators

  • Corxel Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Senior Director, Clinical Operations · Corxel Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-15
Primary Completion
2029-10-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Bulgaria
  • Canada
  • China
  • France
  • Germany
  • Greece
  • Italy
  • Japan
  • Latvia
  • Lithuania
  • Malaysia
  • Portugal
  • Serbia
  • South Korea
  • Spain
  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06990867 on ClinicalTrials.gov